Home > News > Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences
August 11th, 2005
Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences
Abstract:
Nanobac Life Sciences, Inc. announced today that Mission Pharmacal Company, a global pharmaceutical company and leading kidney stone disease reference laboratory, executed an observation rights agreement with Nanobac Life Sciences to observe a multi-center collaboration involving researchers from Nanobac, the University of California, San Francisco (UCSF), and NASA's Johnson Space Center, to study kidney stone formation.
Source:
businesswire
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||